Search
Feed aggregator
Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen
Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen 7/11/2024
Kazia Offers Secondary OS Data to Build FDA Case for Glioblastoma Drug
Kazia Offers Secondary OS Data to Build FDA Case for Glioblastoma Drug 7/11/2024
FDA Rejects Novo’s Once-Weekly Insulin Injection, Cites Manufacturing Process
FDA Rejects Novo’s Once-Weekly Insulin Injection, Cites Manufacturing Process 7/11/2024
FTC to Sue ‘Big Three’ PBMs for Setting Insulin, Other Drug Prices: WSJ
FTC to Sue ‘Big Three’ PBMs for Setting Insulin, Other Drug Prices: WSJ 7/11/2024
FTC Ban That Would Make Switching Jobs Easier Hits Roadblock
FTC Ban That Would Make Switching Jobs Easier Hits Roadblock 7/11/2024
Syntis Bio Launches in Effort to Challenge GLP-1s in Lucrative Weight Loss Ma...
Syntis Bio Launches in Effort to Challenge GLP-1s in Lucrative Weight Loss Ma... 6/11/2024
Ipsen, Genfit’s Elafibranor Wins FDA Approval for Primary Biliary Cholangitis
Ipsen, Genfit’s Elafibranor Wins FDA Approval for Primary Biliary Cholangitis 6/11/2024
Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’
Sage’s Dalzanemdor Shows Effect in Huntington’s Study, Analysts Say Results ‘Underwhelming’ 6/11/2024
Stada Bags European Rights from Alvotech to Biosimilar of Amgen Blockbusters
Stada Bags European Rights from Alvotech to Biosimilar of Amgen Blockbusters 6/11/2024
GSK Appeals Delaware Court’s Decision in Zantac Cases as Plaintiff Drops Lawsuit
GSK Appeals Delaware Court’s Decision in Zantac Cases as Plaintiff Drops Lawsuit 6/11/2024
Lilly Sees More Zepbound Out-of-Pocket Payments as Obesity Pill Nears Phase III Readout
Lilly Sees More Zepbound Out-of-Pocket Payments as Obesity Pill Nears Phase III Readout 6/11/2024
Top 5 Companies Hiring in San Diego
Top 5 Companies Hiring in San Diego 4/11/2024
VC Firm Flagship Raises $3.6B to Create, Support 25 ‘Breakthrough’ Companies
VC Firm Flagship Raises $3.6B to Create, Support 25 ‘Breakthrough’ Companies 7/10/2024
FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream
FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream 7/10/2024
Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger
Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger 7/10/2024
Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data
Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data 7/10/2024
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists 7/10/2024
Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors
Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors 7/10/2024
Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia
Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia 7/10/2024
Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma?
Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma? 7/10/2024
World Pharma News
- U.S. FDA grants full approval to Pfizer's BRAFTOVI combination regimen in first-line metastatic colorectal cancer
- New antibody-drug conjugate strategy to block HIV infection
- Rhododendron-derived drugs now made by bacteria
- Lung cancer drug offers a surprising new treatment against ovarian cancer
- Researchers identify promising Alzheimer's disease drug target